Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Revolution Medicines (RVMD) Accumulated Depreciation & Amortization (2018 - 2025)

Revolution Medicines has reported Accumulated Depreciation & Amortization over the past 8 years, most recently at $28.5 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $28.5 million for Q4 2025, up 30.66% from a year ago — trailing twelve months through Dec 2025 was $28.5 million (up 30.66% YoY), and the annual figure for FY2025 was $28.5 million, up 30.66%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $28.5 million at Revolution Medicines, up from $27.0 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for RVMD hit a ceiling of $28.5 million in Q4 2025 and a floor of $700000.0 in Q1 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $16.2 million (2023), compared with a mean of $12.9 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: grew 14.29% in 2021 and later surged 1641.11% in 2023.
  • Revolution Medicines' Accumulated Depreciation & Amortization stood at $3.1 million in 2021, then increased by 29.03% to $4.0 million in 2022, then increased by 25.0% to $5.0 million in 2023, then soared by 336.46% to $21.8 million in 2024, then skyrocketed by 30.66% to $28.5 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $28.5 million (Q4 2025), $27.0 million (Q3 2025), and $25.0 million (Q2 2025) per Business Quant data.